Highly pure (>98%) recombinant hMIG (human Monokine induced by Interferon-Gamma)
Our Abpromise guarantee covers the use of ab9720 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use a concentration of 0.5 µg/ml.|
|Neutralising||Use at an assay dependent dilution. To yield one-half maximal inhibition [ND50] of the biological activity of hMIG (100.00 ng/ml), a concentration of 5.0 - 7.0 µg/ml of this antibody is required|
|WB||Use 0.1µg for 100.2 cells.|
|IHC-P||Use a concentration of 0.25 - 0.5 µg/ml.|
ab9720 staining MIG in human renal tumor with parenchyma tissue by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent heat mediated antigen retrieval in sodium citrate buffer (pH 6.0). The primary antibody was used at 0.25 ug/ml and incubated with sample at 4°C overnight. A HRP-labeled polymer detection system was used with a DAB chromogen.
ab9720 staining MIG in Human tonsil (periphery) tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked for 5 minutes at 25°C; antigen retrieval was by heat mediation in a citrate buffer. Samples were incubated with primary antibody (1/100) for 30 minutes at 25°C. A Biotin-conjugated Goat anti-rabbit IgG polyclonal (1/500) was used as the secondary antibody.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"